Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Simon Davis, Professor of Molecular Immunology in the MRC TIDU at the MRC WIMM, has been appointed as RDM’s first Entrepreneurship Lead.

As RDM’s first Entrepreneurship Lead, Professor Simon Davis will offer advice on the potential commercial value of new ideas (within his area of scientific expertise); balancing company and scientific interests; securing pump-priming funding; pitching to venture capitalists and industry; making best use of Oxford’s start-up infrastructure; founding companies; and working with scientific advisory boards and boards of directors. Simon will be available to act as a mentor for budding entrepreneurs, particularly among students and post-docs, and can also highlight other routes to engaging the commercial sector, e.g. via consultancy and expert witnessing.

Head of Department Professor Keith Channon says, ‘I very much look forward to working with Simon in his new role as a strong and pro-active advocate of entrepreneurialism, and the further development of entrepreneurial opportunities amongst RDM’s scientific community. This is an important aspect of generating wider impact and benefit from our research’.

Simon comments, ‘I am very pleased to have been appointed as the new RDM Entrepreneurship Lead, so that I can help others to benefit from the extraordinarily rich tech-transfer resources that the University offers, in the ways that we have done in the recent past. I look forward to sharing my experiences and offering advice, and helping turn the great science done here at the RDM into commercially attractive opportunities.’ Simon’s co-developed spinout company MiroBio was acquired by Gilead Sciences for $405m in summer 2022, bringing valuable revenue to the Department.

Recent stories

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Therapy Acceleration Lab achieves Medical Laboratory Accreditation

The Therapy Acceleration Lab (TAL) at the MRC WIMM has been accredited by the United Kingdom Accreditation Service (UKAS) to ISO 15189:2022 – Medical laboratories – Requirements for quality and competence.

Gene editing points to new treatment approach for inherited blood disorder

Researchers at the MRC Weatherall Institute of Molecular Medicine have used genome editing to reactivate an embryonic globin gene, offering a potential new strategy for treating severe α-thalassaemia.

Immune sensor can detect viral infection by monitoring cell’s own RNA

A recent study by the Rehwinkel Group and collaborators reveals a new way the immune sensor MDA5 can recognise viral infection – not only through viral RNA, but by monitoring changes to the cell’s own RNA processing.

New technology helps decode the genetic changes behind disease

Researchers from the Milne, Hughes and Davies Groups have developed a new technology that can reveal new therapeutic targets from common genetic variants linked to disease.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.